Johnson & Johnson Sold Insulin Pumps After Learning of Defects, FDA Says

Johnson & Johnson’s Animas unit kept selling insulin pumps last year after learning of malfunctions with the devices that prompted it to make design changes, the Food and Drug Administration said. The agency faulted the J&J unit for not adequately explaining “why your firm continued to manufacture insulin pumps” after they “had known failures.” The issues with Animas’ One Touch Ping and 2020 pumps prompted a company investigation that started in April, according to the FDA’s letter, which was dated Dec. 27 and released today.

Back to news